IRIS International (NASDAQ: IRIS) is one of 10 public companies in the “Diagnostic & Testing Substances” industry, but how does it compare to its peers? We will compare IRIS International to similar businesses based on the strength of its dividends, analyst recommendations, valuation, institutional ownership, earnings, risk and profitability.
Valuation and Earnings
This table compares IRIS International and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|IRIS International Competitors||$105.21 million||-$43.12 million||502.48|
IRIS International’s peers have higher revenue, but lower earnings than IRIS International. IRIS International is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
IRIS International has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, IRIS International’s peers have a beta of 0.09, meaning that their average stock price is 91% less volatile than the S&P 500.
This table compares IRIS International and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|IRIS International Competitors||-1,255.75%||-1,582.35%||-49.22%|
This is a summary of current ratings and recommmendations for IRIS International and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|IRIS International Competitors||35||75||194||2||2.53|
As a group, “Diagnostic & Testing Substances” companies have a potential upside of 57.89%. Given IRIS International’s peers higher probable upside, analysts clearly believe IRIS International has less favorable growth aspects than its peers.
Insider & Institutional Ownership
68.9% of IRIS International shares are owned by institutional investors. Comparatively, 53.3% of shares of all “Diagnostic & Testing Substances” companies are owned by institutional investors. 9.7% of IRIS International shares are owned by insiders. Comparatively, 13.3% of shares of all “Diagnostic & Testing Substances” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
IRIS International beats its peers on 5 of the 8 factors compared.
IRIS International Company Profile
Mitcham Industries, Inc. is a provider of equipment to the geophysical, oceanographic and hydrographic industries. The Company operates through two segments. The Equipment Leasing segment is primarily engaged in the leasing of seismic equipment to companies in the oil and gas industry across the world. The Equipment Manufacturing and Sales segment is engaged in the design, production and sale of marine seismic equipment, and oceanographic and hydrographic equipment. Its leasing business includes Mitcham Canada ULC, Seismic Asia Pacific Pty Ltd., Mitcham Seismic Eurasia LLC, Mitcham Europe Ltd. and Mitcham Marine Leasing Pte. Ltd. The Equipment Manufacturing and Sales Segment includes its Seamap International Holdings Pte, Ltd. (Seamap) business and Klein Marine Systems, Inc. (Klein). Seamap designs, manufactures and sells a range of products for the seismic, hydrographic and offshore industries. Klein develops and manufactures high performance side scan sonar systems.
What are top analysts saying about IRIS International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for IRIS International Inc. and related companies.